AtriCure entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit.

“We are pleased to have Silicon Valley Bank as a partner,” said Andy Wade, senior vice president and chief financial officer of AtriCure. “This loan facility strengthens our balance sheet and provides financial flexibility, at a low cost of capital, to drive to profitability in 2018.”

Tom Hertzberg, director in the Life Science and Healthcare practice at Silicon Valley Bank, commented, “We’re pleased to continue our partnership with AtriCure as the company works to expand and scale its portfolio of atrial fibrillation solutions to improve patients’ lives. Our aim is to provide the AtriCure team with the right financing, connections and global services that they need to meet their corporate objectives.”

AtriCure is a medical device company providing innovative atrial fibrillation solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation.